双联抗血小板治疗可显著降低急性冠状动脉综合征,尤其是经皮冠状动脉介入治疗术后患者的再发缺血事件和死亡风险。但治疗后常导致患者消化道出血风险增加,加用质子泵抑制剂(PPI)可降低该风险,已成为临床常规治疗。但近年来,氯吡格雷与PPI间的相互作用是否导致心血管事件的增加,倍受临床医生关注,引发了激烈的讨论。从目前累积的证据看,PPI降低氯吡格雷药物活 Dual antiplatelet therapy significantly reduced acute coronary syndromes, especially the risk of recurrent ischemic events and death in patients undergoing percutaneous coronary intervention. But often lead to increased risk of gastrointestinal bleeding in patients after treatment, plus proton pump inhibitor (PPI) can reduce the risk, has become a routine clinical treatment. However, in recent years, the interaction between clopidogrel and PPI lead to increased cardiovascular events, much of the clinician’s attention, triggered a heated discussion. From the accumulated evidence so far, PPI reduces clopidogrel drug activity